Histopathologic response to neoadjuvant chemotherapy: Prognostic value independent of BRCA status or bevacizumab use

The Chemotherapy Response Score (CRS) has been suggested to be a prognostic marker of relapse, platinum sensitivity, and survival in ovarian cancer (OC). The aim of the present study was to validate the utility of a three-tier CRS and determine if its prognostic value is independent of BRCA status or the use of neoadjuvant bevacizumab.